検索
Repare Therapeutics Inc
RPTXウォッチリストに追加
2.650USD
0.0000.00%
終値 05/15, 16:00（ET）15分遅れの株価
114.24M時価総額
損失額直近12ヶ月PER
詳細情報 Repare Therapeutics Inc 企業名
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Incの企業情報
企業コードRPTX
会社名Repare Therapeutics Inc
上場日Jun 19, 2020
最高経営責任者「CEO」Forte (Steve)
従業員数129
証券種類Ordinary Share
決算期末Jun 19
本社所在地7210 Frederick-Banting, Suite 100
都市ST-LAURENT
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号H4S 2A1
電話番号18574127018
ウェブサイトhttps://www.reparerx.com/
企業コードRPTX
上場日Jun 19, 2020
最高経営責任者「CEO」Forte (Steve)
Repare Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-100.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-146.62%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-100.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025Q3
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Switzerland
11.62M
0.00%
United States
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Feb 1
更新時刻: Sun, Feb 1
株主統計
種類
株主統計
株主統計
比率
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
他の
71.82%
株主統計
株主統計
比率
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
他の
71.82%
種類
株主統計
比率
Hedge Fund
13.86%
Investment Advisor/Hedge Fund
11.24%
Investment Advisor
9.70%
Private Equity
7.74%
Research Firm
0.76%
Individual Investor
0.31%
Venture Capital
0.27%
他の
56.12%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
116
24.72M
57.35%
-9.60M
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Blue Owl Capital Holdings LP
--
0%
+71.16K
-100.00%
OrbiMed Advisors, LLC
--
0%
+124.40K
-100.00%
Shay Capital LLC
--
0%
+2.87M
-100.00%
Redmile Group, LLC
--
0%
--
--
MPM Capital Inc.
--
0%
--
--
Renaissance Technologies LLC
--
0%
+257.20K
-100.00%
Citadel Advisors LLC
--
0%
-460.38K
-100.00%
Rangeley Capital LLC
--
0%
+641.95K
-100.00%
Acadian Asset Management LLC
--
0%
+50.37K
-100.00%
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
Avantis US Equity ETF
比率0%
SPDR S&P International Small Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
